Maven Capital Partners and YFM Equity Partners, have announced the completion of a £6.5m Series A investment for Biorelate. A group of angel investors from the Manchester Tech Trust also participated in the round.

Founded in 2014 and led by Daniel Jamieson, Biorelate curates dark biomedical knowledge to empower drug discovery with its proprietary AI platform, Galactic AI™. Galactic AI’s innovative technology uniquely combines natural language processing (NLP) and machine learning (ML) to capture highly valuable biomedical data that pharmaceutical and life sciences organisations can utilise to improve decision making in their drug discovery programs.